It appears to. Research into a range of innovative medical treatments have found that studies of efficacy tend to significantly underrepresent people of color, potentially leading researchers to miss potential benefits or side effects. For example, Blacks have been found to be highly underrepresented in trials of new psychedelic therapies for mental health, specifically those for PTSD treatments, although they tend to experience high rates of PTSD and have been found in surveys to be open to trying psychedelic interventions. Activists and legislators have urged researchers and companies to open their clinical trials to a wider range of subjects to eliminate potential bias and make new treatments available to all communities as soon as they can.